°£¼¼Æ÷¾Ï°ú °£°æÈÀÇ °£À̽Ä-°£Áٱ⼼Æ÷ Ä¡·á ±ÇÀ§ÀÚ·Î ¸ö°ú ¸¶À½À» ÇÔ²² Ä¡·áÇÏ´Â ÀÇ»ç
| Á¦ ¸ñ | Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis. |
|---|---|
| ¹ßÇ¥³âµµ | 2024 |
| ¹ßÇ¥Áö | Frontiers in Immunology |
| Á¦ ¸ñ | The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study. |
|---|---|
| ¹ßÇ¥³âµµ | 2024 |
| ¹ßÇ¥Áö | Clinical and Molecular Hepatology |
| Á¦ ¸ñ | Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups. |
|---|---|
| ¹ßÇ¥³âµµ | 2024 |
| ¹ßÇ¥Áö | Gut & Liver |
| Á¦ ¸ñ | The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease. |
|---|---|
| ¹ßÇ¥³âµµ | 2024 |
| ¹ßÇ¥Áö | Diagnostics (Basel) |
| Á¦ ¸ñ | Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation |
|---|---|
| ¹ßÇ¥³âµµ | 2024 |
| ¹ßÇ¥Áö | Hepatology International |
| Á¦ ¸ñ | Extracellular Superoxide Dismutase Attenuates Hepatic Oxidative Stress in Nonalcoholic Fatty Liver Disease through the Adenosine Monophosphate-Activated Protein Kinase Activation |
|---|---|
| ¹ßÇ¥³âµµ | 2023 |
| ¹ßÇ¥Áö | Antioxidants(Basel). |
| Á¦ ¸ñ | Intrahepatic infiltration of activated CD8+ T cells and mononuclear phagocyte is associated with idiosyncratic drug-induced liver injury |
|---|---|
| ¹ßÇ¥³âµµ | 2023 |
| ¹ßÇ¥Áö | Frontiers in Immunology |
<¸»±â ÁøÇ༺ °£¼¼Æ÷¾Ï Ä¡·á ºÐ¾ß> °£¼¼Æ÷¾Ï Ä¡·á·Î ¸ÞÆ®·Î³ë¹Í Ä¡·á¹ý(±âÁ¸ÀÇ ÀÏȸ¼º Ä¡·áÀÎ »öÀü¼ú, ÀýÁ¦¼ú·Î´Â Ä¡·á°¡ ¾î·Á¿î ¸»±â °£¾ÏÀ» ¸ÞÆ®·Î³ð°£¼¼Æ÷¾ÏÀÇ Æ¯¼º¿¡ ¸Â°Ô, °£µ¿¸Æ¿¡ Ç×¾ÏÁ¦ ÁÖÀÔÀ» 3Àϰ£ Àå½Ã°£¿¡ °ÉÃÄ ¶ÈµüÀÌ ¹æ½ÄÀ¸·Î ÁÖÀÔ)À¸·Î Ä¡·áÇÑ ¿¬±¸¸¦ ±¹Á¦ ÇмúÁö¿¡ 10Æí ÀÌ»ó ¹ßÇ¥ÇÑ ¾÷Àû
¿ÀÄɽºÆ®¶óÀÇ Àü ±¸¼º¿øÀÌ ¾Æ¸§´Ù¿î ÈÀ½À» À§ÇØ ÃÖ¼±À» ´ÙÇØ ¿¬ÁÖÇϵí, º¹ÀâÇÏ°í ¾î·Á¿î °£¾Ï Ä¡·á¸¦ À§ÇØ ¿©·¯ ÀÓ»ó°ú Àü¹® ±³¼öµéÀÌ °¢ÀÚÀÇ Ä¡·á¹ýÀ» ´ÙÇÐÁ¦ ȸÀǸ¦ ÅëÇØ Á¶À²ÇÏ°í ¸ÂÃãÇü Á¢±ÙÀ» ÅëÇØ ¿ì¼±ÀûÀ¸·Î ȯÀÚ°¡ °¡Àå Æí¾ÈÇÏ°Ô Ä¡·á¹ÞÀ» ¼ö ÀÖµµ·Ï Çϸç, ÃÖ°íÀÇ Ä¡·á °á°ú¸¦ ¾òµµ·Ï ÇÒ¶§°¡ °¡Àå ÇູÇÕ´Ï´Ù.
°£¾ÏÀ» Áø´Ü¹Þ°Å³ª, °£°æÈ¸¦ Áø´Ü ¹Þ´õ¶óµµ Á¶±â Áø´ÜÇÏ¸é ¿ÏÄ¡µÉ ¼ö ÀÖ°í, ½ÉÇÏ°Ô ÁøÇàµÇ¾îµµ ÁÁÀº Ä¡·áÁ¦°¡ ÀÖÀ¸´Ï, Àý´ë Æ÷±âÇÏÁö ¸»°í ÀÇ»ç¿Í »óÀÇÇØ¼ ȯÀںп¡°Ô ¸Â´Â Ä¡·á¸¦ ²À ¹ÞÀ¸½Ã±æ ±ÇÇØµå¸³´Ï´Ù.

°¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿øÀº 80¿© ³âÀÇ °¡Å縯 ÀÇ·á ¿ª·®À» ¹ÙÅÁÀ¸·Î, ÃÖ÷´Ü Àåºñ, ¾ÈÀüȯ ȯ°æ, ¿ì¼öÇÑ Áø·á ½Ã½ºÅÛÀ» °®Ãß°í ÀÖ½À´Ï´Ù. À̽Ä, ½ÉÀå, ¾Ï µî ÁßÁõ Áúȯ °í°´µé¿¡°Ô ¿ì¼öÇÑ ÀÇ·áÁøÀÌ ¼öÁØ ³ôÀº Ä¡·á¸¦ Á¦°øÇϸç, ÀÀ±ÞÀÇ·á¼¾ÅÍ¿Í ¼Ò¾ÆÀÀ±Þ½ÇÀ» ¿î¿µÇÏ¿© Áö¿ª»çȸÀÇ ÀÀ±Þ ȯÀڵ鿡°Ô ÇʼöÀûÀÎ ÀÇ·á ¼ºñ½º¸¦ Áö¿øÇÕ´Ï´Ù. ¶ÇÇÑ, °¡Å縯 ÀÇ·á±â°üÀ¸·Î ÀÇ·á Ãë¾à°èÃþÀ» Áö¿øÇÏ´Â µîÀÇ »çȸ°øÇå Ȱµ¿À» Áö¼ÓÀûÀ¸·Î Àü°³Çϰí ÀÖ½À´Ï´Ù.
¼¿ïƯº°½Ã ÀºÆò±¸ ÅëÀÏ·Î 1021